Cost-effectiveness of Dabigatran Compared With Rivaroxaban for Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in China.

Dong, Shu-Jie

Cost-effectiveness of Dabigatran Compared With Rivaroxaban for Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in China. [electronic resource] - Clinical therapeutics 01 2020 - 144-156.e1 p. digital

Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't

1879-114X

10.1016/j.clinthera.2019.11.011 doi


Aged
Anticoagulants--economics
Atrial Fibrillation--drug therapy
China
Cost-Benefit Analysis
Dabigatran--economics
Embolism--prevention & control
Female
Humans
Male
Markov Chains
Models, Economic
Quality-Adjusted Life Years
Rivaroxaban--economics
Stroke--prevention & control
Treatment Outcome